Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-68108-2
Affiliations:
4
Authors:
12
Go to article
Institutions Authors Share
Tianjin Medical University Cancer Institute and Hospital, TMU, China
11.000000
11.000000
 0.92
Tianjin Medical University (TMU), China
1.000000
 0.08
Interested in Oncology and Carcinogenesis?